RU2015136260A - Противовирусные соединения - Google Patents
Противовирусные соединения Download PDFInfo
- Publication number
- RU2015136260A RU2015136260A RU2015136260A RU2015136260A RU2015136260A RU 2015136260 A RU2015136260 A RU 2015136260A RU 2015136260 A RU2015136260 A RU 2015136260A RU 2015136260 A RU2015136260 A RU 2015136260A RU 2015136260 A RU2015136260 A RU 2015136260A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- triazol
- diamine
- pyridin
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (37)
1. Соединение формулы I
где
А представляет собой ненасыщенный или частично насыщенный моноциклический или бициклический гетероарил, возможно замещенный одним или более А'; и
каждый А' независимо представляет собой галоген, галоген низший алкил, низший алкил, или оксо;
или его фармацевтически приемлемая соль.
2. Соединение по п. 1, где А представляет собой пиридил, возможно замещенный одним или более А'.
3. Соединение по п. 2, где один А' представляет собой галоген или два А' представляют собой галоген.
4. Соединение по п. 2, где А' представляет собой галоген низший алкил.
5. Соединение по п. 1, где А представляет собой тиазолил, возможно замещенный одним или более А'.
6. Соединение по п. 5, где А' представляет собой низший алкил.
7. Соединение по п. 1, где А представляет собой тиофенил, возможно замещенный одним или более А'.
8. Соединение по п. 7, где А' представляет собой галоген.
9. Соединение по п. 1, где А представляет собой пиридазинон, возможно замещенный одним или более А'.
10. Соединение по п. 1, где один А' представляет собой низший алкил, а другой представляет собой галоген.
11. Соединение по п. 1, где А представляет собой фталазинон или имидазопиридинил, возможно замещенный одним или более А'.
12. Соединение, выбранное из группы, состоящей из:
N3-(2-хлор-пиридин-4-ил)-1H-[1,2,4]триазол-3,5-диамин;
N3-(6-трифторметил-пиридин-3-ил)-1H-[1,2,4]триазол-3,5-диамин;
N3-(2,6-дихлор-пиридин-4-ил)-1H-[1,2,4]триазол-3,5-диамин;
N3-(6-трифторметил-пиридин-2-ил)-1Н-[1,2,4]триазол-3,5-диамин;
N3-(4-трет-бутил-тиазол-2-ил)-1H-[1,2,4]триазол-3,5-диамин;
N3-(4-трифторметил-пиридин-2-ил)-1H-[1,2,4]триазол-3,5-диамин;
N3-(5-хлор-тиофен-3-ил)-1H-[1,2,4]триазол-3,5-диамин;
4-(5-амино-1H-[1,2,4]триазол-3-иламино)-6-хлор-2-метил-2Н-пиридазин-3-он;
6-(5-амино-1Н-[1,2,4]триазол-3-иламино)-2H-фталазин-1-он;
6-(5-амино-1H-[1,2,4]триазол-3-иламино)-2-метил-2H-фталазин-1-он;
N3-Имидазо[1,2-а]пиридин-6-ил-1Н-[1,2,4]триазол-3,5-диамин; и
N3-Имидазо[1,2-а]пиридин-7-ил-1Н-[1,2,4]триазол-3,5-диамин.
13. Способ предотвращения инфекции вируса гепатита С (ВГС), содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединения по любому из пп. 1-12.
14. Способ по п. 13, дополнительно включающий введение нуждающемуся в этом пациенту терапевтически эффективного количества супрессора иммунной системы.
15. Способ лечения инфекции вируса гепатита С (ВГС), содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединения по любому из пп. 1-12.
16. Способ по любому из пп. 13-15, дополнительно включающий введение комбинации противовирусных агентов, которые ингибирует репликацию ВГС.
17. Способ по любому из пп. 13-15, дополнительно включающий введение модулятора иммунной системы или противовирусного агента, который ингибирует репликацию ВГС, или их комбинацию.
18. Способ по п. 17, где модулятор иммунной системы представляет собой интерферон или химически дериватизированный интерферон.
19. Способ по п. 17, где противовирусный агент выбран из группы, состоящей из ингибитора протеазы ВГС, ингибитора полимеразы ВГС, ингибитора геликазы ВГС, ингибитора NS5A ВГС, или любые их комбинации.
20. Композиция, содержащая соединение по любому из пп. 1-12 и фармацевтически приемлемый эксципиент.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361772919P | 2013-03-05 | 2013-03-05 | |
US61/772,919 | 2013-03-05 | ||
PCT/EP2014/054032 WO2014135483A1 (en) | 2013-03-05 | 2014-03-03 | Antiviral compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015136260A true RU2015136260A (ru) | 2017-04-10 |
Family
ID=50190460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015136260A RU2015136260A (ru) | 2013-03-05 | 2014-03-03 | Противовирусные соединения |
Country Status (11)
Country | Link |
---|---|
US (1) | US9896433B2 (ru) |
EP (1) | EP2964634B1 (ru) |
JP (1) | JP6122514B2 (ru) |
KR (1) | KR20150113203A (ru) |
CN (1) | CN105026386B (ru) |
BR (1) | BR112015018623A2 (ru) |
CA (1) | CA2900321A1 (ru) |
HK (1) | HK1216884A1 (ru) |
MX (1) | MX2015011126A (ru) |
RU (1) | RU2015136260A (ru) |
WO (1) | WO2014135483A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014135472A1 (en) * | 2013-03-05 | 2014-09-12 | F. Hoffmann-La Roche Ag | Antiviral compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064211A1 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
DE10123586A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
CN1738615A (zh) * | 2002-11-15 | 2006-02-22 | 沃泰克斯药物股份有限公司 | 用作蛋白质激酶的抑制剂的二氨基***类 |
AU2012363873B2 (en) | 2012-01-06 | 2017-11-23 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US20140010783A1 (en) * | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
-
2014
- 2014-03-03 MX MX2015011126A patent/MX2015011126A/es unknown
- 2014-03-03 RU RU2015136260A patent/RU2015136260A/ru unknown
- 2014-03-03 JP JP2015559518A patent/JP6122514B2/ja active Active
- 2014-03-03 KR KR1020157024038A patent/KR20150113203A/ko not_active Application Discontinuation
- 2014-03-03 EP EP14707410.8A patent/EP2964634B1/en not_active Not-in-force
- 2014-03-03 CN CN201480011128.6A patent/CN105026386B/zh not_active Expired - Fee Related
- 2014-03-03 CA CA2900321A patent/CA2900321A1/en not_active Abandoned
- 2014-03-03 BR BR112015018623A patent/BR112015018623A2/pt not_active Application Discontinuation
- 2014-03-03 US US14/766,646 patent/US9896433B2/en not_active Expired - Fee Related
- 2014-03-03 WO PCT/EP2014/054032 patent/WO2014135483A1/en active Application Filing
-
2016
- 2016-04-25 HK HK16104701.4A patent/HK1216884A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20150376165A1 (en) | 2015-12-31 |
EP2964634A1 (en) | 2016-01-13 |
CA2900321A1 (en) | 2014-09-12 |
KR20150113203A (ko) | 2015-10-07 |
WO2014135483A1 (en) | 2014-09-12 |
CN105026386B (zh) | 2017-08-01 |
JP6122514B2 (ja) | 2017-04-26 |
BR112015018623A2 (pt) | 2017-07-18 |
HK1216884A1 (zh) | 2016-12-09 |
MX2015011126A (es) | 2015-11-11 |
CN105026386A (zh) | 2015-11-04 |
JP2016510014A (ja) | 2016-04-04 |
EP2964634B1 (en) | 2018-05-30 |
US9896433B2 (en) | 2018-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016138735A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
JP2019034943A5 (ru) | ||
EA201891876A1 (ru) | Тетрациклические пиридоновые соединения в качестве противовирусных средств | |
JP2007534662A5 (ru) | ||
JP2017523225A5 (ru) | ||
JP2013209405A5 (ru) | ||
EA200800178A1 (ru) | Ингибиторы вируса гепатита с (hcv) | |
JP2012513479A5 (ru) | ||
RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
JP2014015465A5 (ru) | ||
RU2007116176A (ru) | Бициклические пиримидины, ингибирующие hcv | |
JP2015520140A5 (ru) | ||
EA201201235A1 (ru) | Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv | |
JP2017505314A5 (ru) | ||
JP2014521688A5 (ru) | ||
JP2016515561A5 (ru) | ||
WO2011156543A3 (en) | Inhibitors of hcv ns5a protein | |
ATE475660T1 (de) | Antivirale verbindungen | |
EA201991174A1 (ru) | Комбинация двух противовирусных препаратов для лечения гепатита c | |
RU2018142988A (ru) | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена | |
RU2015114543A (ru) | Способы лечения гепатита с | |
JP2016501185A5 (ru) | ||
RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
JP2018529671A5 (ru) | ||
RU2018114077A (ru) | Биарильное производное и содержащее его лекарственное средство |